Non-rifampin rifamycins in TB/HIV
|
|
|
- Jonathan Craig
- 5 years ago
- Views:
Transcription
1 Non-rifampin rifamycins in TB/HIV Richard E. Chaisson, MD Johns Hopkins University Center for TB Research Consortium to Respond Effectively to the AIDS-TB Epidemic
2 Rifamycins for TB Inhibit bacterial DNA-dependent RNA polymerase Key sterilizing drug in TB treatment basis of short-course therapy Three products available Rifampin Rifapentine Rifabutin
3 Selected Pharmacokinetic Properties of Rifamycins Property Rifampin Rifabutin Rifapentine Half life (T1/2), h Cmax (mcg/l) MIC (mcg/l) Cytochrome P450 induction Effect of cytochrome P450 inhibition Effect of food AUC - AUC Adapted from: Burman et al., Clin Pharmacokin, 2001;40:
4 Important Drug Interactions with Rifampin* Protease inhibitors RIF decreases levels >80%, except some RTVboosted regimens Increased hepatotoxicity with LPV/r and SQV/r NNRTIs RIF decreases NVP 40-50%, EFV 20-35%, ETV significantly CCR5 Inhibitors RIF reduces maraviroc by 63% Integrase inhibitors RIF reduces raltegravir by 40-60% *similar effects likely with rifapentine
5 Important Drug Interactions with Rifabutin Protease inhibitors Rifabutin decreases levels >20-30% RTV and azoles increase RBT levels significantly, causing uveitis and other toxicities dose reduction necessary NNRTIs Rifabutin has minor effect on NVP and EFV EFV increases RBT clearance dose escalation necessary CCR5 Inhibitors no information Integrase inhibitors no information
6 Potential Role of Rifabutin and Rifapentine in HIV-related Tuberculosis Rifabutin Permit treatment of TB in HIV-infected patients on boosted PI regimens Rifapentine Shortening course of TB treatment in HIV+ and HIV- individuals Short-course preventive therapy for HIVinfected people with latent TB
7 Rifabutin for treating HIV-related TB TBTC Study 23 Twice weekly RBT/INH for HIV/TB High efficacy for TB 5/156 HIV+ patients had relapse/failure with acquired rifampin resistance All CD4 <60 CDC recommendation do not use highly intermittent treatment for HIV+ patients with CD4 <100 MMWR 2002;51:214-5
8 Increasing regimen potency by increasing rifamycin exposure in a mouse model Jayaram et al Antimicrob Agents Chemother 2003;47:2118
9 Optimizing rifamycin exposure by using rifapentine Half-life hours (rifampin 2-5 hours) MIC 0.05 mcg/ml (rifampin 0.15 mcg/ml) Less potent inducer of cytochrome P450 than rifampin FDA-approved for TB treatment at dose of 600 mg (10 mg/kg) given twice weekly
10 Log 10 CFU per lung Bactericidal activity of daily regimens in mice logs 4 logs? R 10 H 25 Z 150 R 10 M 100 Z 150 P 10 M 100 Z Weeks Rosenthal et al., PLoS Medicine 2007 RIF10 INH PZA RIF10 MOX PZA RPT10 MOX PZA
11 Rifapentine Rx studies in humans P+M PK (JHU/NIH) Complete development for registration of a short regimen P1: dose ranging PK D14 safety; mg/d (JHU) P1: P + Raltegravir PK (CDC) P2: P10HZE (5/7) 8 weeks (CDC TBTC Study 29) P2: P10HZE P7.5HZE (7/7) efficacy at 8 weeks (JHU/FDA) P2:P7.5HZM (7/7) 8 weeks (JHU/NIH) Adapted from D. Leboulleux, Sanofi-aventis
12 Novel TB Preventive Regimens in HIV- Infected Adults in Soweto: Preliminary Results Neil Martinson, Grace Barnes, Reginah Msandiwa, Lawrence Moulton, Glenda Gray, James McIntyre, Harry Hausler, Malathi Ram, Richard E. Chaisson Perinatal HIV Research Unit Johns Hopkins University Center for TB Research Funded by NIAID R01 AI48526 and USAID
13 Methods Open label, randomized trial Soweto, South Africa Eligibility: HIV+ TST+ (>=5mm) adults (>=18 yrs) not eligible for HAART No evidence of liver disease No active TB Active TB: CXR, symptom screen and AFB smear and TB culture. Endpoint TB-free survival
14 Novel Regimens for TB Preventive Therapy Short-course Rifapentine 900mg + INH 900mg weekly 12 doses effective in animal model, convenient for patients Rifampin 600 mg + INH 600mg twice weekly 24 doses effective in one trial, widely available Long INH 300mg daily continuously may be effective to prevent re-infection Standard of care INH 300mg daily for 6 months
15 Study Flow and Recruitment Screened 1528 Eligible 1176 (77%) Not Eligible 352 (23%) Enrolled 1150 (98%) Confirmed TB 78 (22%) 77 Smear negative RPT/INH RIF/INH INH INH Continuous 164
16 Baseline Characteristics RPT/INH (%) RIF/INH (%) INH -6 (%) INH - Cont (%) All (%) Median Age % Women Education Grade Grade Diploma Employment Employed PPD (mm) Mean Range
17 Baseline Characteristics - cont Characteristic RPT/INH RIF/INH INH-6 INH- Cont Overall Weight (kg) Mean Weight CD4 count (cells/mm 3 ) Median Range HIV Viral Load (copies/ml) Median 18,400 10,800 15,900 16,200 15,200
18 Primary Outcomes by Study Arm Outcome RPT/INH-3 (N=329) RIF/INH-3 (N=329) INH-cont (N=164) INH-6 (N=328) Median F/U (yrs) TB Cases TB incidence (per 100 PY) TB incidence Rate ratio (ref) TB or death TB or death Rate ratio (ref)
19
20
21 Resistance Testing of Isolates Arm Resistance Testing (N) MDR (N) INH (N) R (N) Resistant to Strept. (N) E (N) RPT/INH RIF/INH INH INH/Cont Total
22 Serious Adverse Events by Study Arm Study Arm RPT/INH RIF/INH INH-6 INH-Cont N (Rate*) N (Rate) N (Rate) N (Rate) Total N (Rate) Hospitalization 95 (29.0) 89 (27.1) 104 (31.8) 38 (23.2) 326 (28.4) Pregnancy 81 (24.7) 74 (22.5) 49 (15.0) 31 (18.9) 235 (20.5) Grade 3 Toxicity 17 (5.2) 15 (4.6) 17 (5.2) 35 (21.3) 105 (9.1) Grade 4 Toxicity 4 (1.2) 9 (2.7) 14 (4.3) 18 (11.0) 45 (3.9) All Adverse Events 250 (76.2) 244 (74.2) 241 (73.7) 150 (91.5) 885 (77.1) Rate= per 100 enrolled persons
23 Conclusions RPT/INH-3, RIF/INH-3 and H-cont are not superior to INH-6, but may be as efficacious. INH-cont had the lowest TB rate but significantly higher adverse event rate All 3 experimental regimens had lower risks of TB/Mortality, but not significantly so
24 Conclusions The shorter two novel regimens may be useful to improve adherence to TB preventive therapy in HIV-infected adults in sub-saharan Africa. We cannot make recommendations about the use of continuous isoniazid preventive treatment.
25 Rifamycins for TB Summary Rifamycins essential for TB therapy Rifampin is safe and effective for HIV/TB patients on efavirenz Rifabutin allows use of boosted PI regimens to treat HIV in patients on TB therapy Rifapentine has the potential to shorten TB therapy significantly Rifapentine is a promising agent for shortcourse TB preventive therapy
The role of ART and IPT in TB prevention: Latest updates
The role of ART and IPT in TB prevention: Latest updates Richard E. Chaisson, MD Center for Tuberculosis Research Johns Hopkins University Consortium to Respond Effectively To the AIDS-TB Epidemic (CREATE)
TB Prevention in PLHIV: Options Other Than Isoniazid. Johns Hopkins Center for Tuberculosis. Research. Richard E. Chaisson, MD
TB Prevention in PLHIV: Options Other Than Isoniazid Johns Hopkins Center for Tuberculosis Richard E. Chaisson, MD Research Johns Hopkins University Center for Tuberculosis Research Consortium to Respond
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI
Preventing TB: Recent Research Results and Novel Short Course Therapy for LTBI Constance A. Benson, M.D. Professor of Medicine Director, UCSD AntiViral Research Unit PI, CD4 Collaborative HIV Clinical
"Sterilization of TB disease in
11/1/1 "Sterilization of TB disease in mice " Jacques Grosset Pharmacodynamics of daily rifapentine and rifampin in mice Free rifam mycin Concentrati ion/mic 1 1 Rifapentine (1mg/kg) Free rifam mycin Concentrati
TB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Recent Findings & Activities of the Tuberculosis Trials Consortium (TBTC) Bill Burman Denver TBTC Unit & Denver Public Health Recent findings
HIV and TB coinfection: Updates. Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University
HIV and TB coinfection: Updates Awewura Kwara, MD, MPH &TM Associate Professor, Alpert Medical School of Brown University Learning objectives Identify the optimal timing of antiretroviral therapy in patients
TB prevention studies in PLHIV: recent updates and what can they tell us for the future?
TB prevention studies in PLHIV: recent updates and what can they tell us for the future? Richard E. Chaisson, MD Center for AIDS Research Center for TB Research Johns Hopkins University TB/HIV Working
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
5. HIV-positive individuals treated with INH should receive Pyridoxine (B6) 25 mg daily or 50 mg twice/thrice weekly on the same schedule as INH
V. TB and HIV/AIDS A. Standards of Treatment and Management The majority of TB treatment principles apply to persons with HIV/AIDS who require treatment for TB disease. The following points are either
8/28/2017. Learning Objectives. After attending this presentation, learners will be able to:
New and Noteworthy in Tuberculosis Diagnostics and Treatment Susan Swindells, MBBS Professor of Internal Medicine University of Nebraska Medical Center Omaha, Nebraska San Antonio, Texas: August 21 to
ACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
TB in the Patient with HIV
TB in the Patient with HIV Lisa Y. Armitige, MD, PhD May 11, 2017 TB Intensive May 9 12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Lisa Y. Armitige, MD, PhD, has the following disclosures to
TBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
TB Intensive San Antonio, Texas May 7-10, 2013
TB Intensive San Antonio, Texas May 7-10, 2013 TB in the HIV Patient Lisa Armitige, MD, PhD May 09, 2013 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:
TB Intensive San Antonio, Texas August 2-5, 2011 TB/HIV Co-Infection Lisa Armitige, MD, PhD August 4, 2011 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests No relevant
Research gaps for eliminating TB deaths among people living with HIV. GJ Churchyard 25 th July 2017
Research gaps for eliminating TB deaths among people living with HIV GJ Churchyard 25 th July 2017 Overview Research gaps for preventing TB deaths among PLWHIV Programmatic management of LTBI Tests of
What He Said: Rifampin versus Rifapentine
What He Said: Rifampin versus Rifapentine Charles A. Peloquin, Pharm.D. Director Infectious Disease Pharmacokinetics Laboratory Professor, College of Pharmacy & The Emerging Pathogens Institute University
TB/HIV Co-Infection. Tuberculosis and HIV
TB Intensive Tyler, Texas June 2-4, 2010 TB/HIV Co-Infection Lisa Y Armitige, MD, PhD June 3, 2010 Tuberculosis and HIV Co-Infection Lisa Y Armitige, MD, PhD Medical Consultant Heartland National TB Center
Case Management of the TB/HIV Infected Patient
TB Nurse Case Management San Antonio, Texas December 8-10, 2009 Case Management of the TB/HIV Infected Patient Sarah Hoffman, MPH, MSN, ACRN December 9, 2009 TB/HIV: Considerations in the Care of the Coinfected
TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.
TB Intensive Tyler, Texas December 2-4, 2008 Tuberculosis and HIV Co-Infection Lisa Y. Armitige, MD, Ph.D. December 4, 2008 Tuberculosis and HIV Co Infection Lisa Y. Armitige, MD, PhD Assistant Professor
Tuberculosis Intensive
Tuberculosis Intensive San Antonio, Texas April 3 6, 2012 TB in the HIV Patient Lisa Armitige, MD, PhD April 6, 2012 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
Treatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD
Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J. Regional Chest Clinic New Jersey State TB Physician Advisory Board Cooper Univ. Hospital EIP Program TB and HIV
TB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
Application to add rifapentine to the Essential List of Medicines as a medicine for the treatment of latent tuberculosis infection
Application to add rifapentine to the Essential List of Medicines as a medicine for the treatment of latent tuberculosis infection 1 P age Table of contents Abbreviations.... page 3 Executive summary.....page
CDC's Tuberculosis Trials Consortium
CDC's Tuberculosis Trials Consortium Kayla Laserson, Andrew Vernon, Erin Bliven, Neil Schluger, William Burman, Fred Gordin, Tim Sterling, Carol Dukes Hamilton, Debra Benator, Donna Conwell, Nancy Dianis,
Drug Interactions with ART and New TB drugs: What Do We Know?
Drug Interactions with ART and New TB drugs: What Do We Know? HIV/TB Research Frontiers Meeting 20 th Conference on Retroviruses and Opportunistic Infections 3 March 2013 Presented by: Kelly Dooley MD,
Pharmacology and Pharmacokinetics of TB Drugs Part I
Pharmacology and Pharmacokinetics of TB Drugs Part I Charles A. Peloquin, Pharm. D. Professor, and Director Infectious Disease Pharmacokinetics Laboratory College of Pharmacy and The Emerging Pathogens
HIV/TB Co infection TB Clinical Intensive October 11, 2018
HIV/TB Co infection TB Clinical Intensive October 11, 2018 Gabriel Chamie, MD, MPH Associate Professor of Medicine Division of HIV, Infectious Diseases & Global Medicine UCSF/San Francisco General Hospital
Principles of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011
TB/HIV CO-INFECTION ADULT & CHILDREN (INCLUDING INH PROPHYLAXIS) ART Treatment Guideline Training 31 st January to 4 th February, 2011 OUTLINE Background Global Incidence The Problem" The 3 I s Drug Resistant
CLINICAL VIGNETTE: Patient 1. Approach to Co-infection with TB and HIV: TB and HIV Co-infection: Some Resources. Goals and Objectives
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb http://www.umdnj.edu/globaltb/coretbresources.htm Approach to Co-infection with TB and HIV: 2011 Henry Fraimow, MD Consultant, Southern N.J.
What's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
Disclosures. Public Health Motivation 6/6/2012. The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next?
The 12-Dose INH-Rifapentine Once-Weekly DOT Regimen: What Next? NTCA Conference June 14, 2012 John Jereb, FSEB, DTBE, CDC Special thanks to Christine Ho, Elsa Villarino, and Andrey Borisov The findings
Clinical Vignette: Patient 1. Approach to Co-infection with TB. TB and HIV Co-infection: Some Resources. Objectives.
TB and HIV Co-infection: Some Resources http://www.cdc.gov/tb AETC Natl Resource Center: http://www.aidsetc.org Approach to Co-infection with TB and HIV: 2012 Henry Fraimow, MD Consultant, Southern N.J.
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
Diagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
Contact Investigation and Prevention in the USA
Contact Investigation and Prevention in the USA George D. McSherry, MD Division of Infectious Disease Penn State Children s Hospital Pediatric Section TB Center of Excellence Rutgers Global Tuberculosis
HIV/TB. Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease. TB Clinical Intensive Seattle, WA June 16-17, 2016
HIV/TB Sylvia LaCourse MD, MPH Department of Medicine, Division of Allergy & Infectious Disease TB Clinical Intensive Seattle, WA June 16-17, 2016 Roadmap for today s talk HIV/TB Epidemiology Global US
HIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
NIAID TB Therapeutic Clinical Research Priorities. Prognostic biomarkers for disease progression, treatment response/relapse
NIAID TB Therapeutic Clinical Research Priorities New drugs and combinations for DS and DR TB: Efficient Phase I and II evaluations Phase III Killing Persisters Sterilizing activity is crucial Prognostic
Rifabutin for TB for people on ART
Rifabutin for TB for people on ART Reuben Granich WHO HIV/AIDS Department HIV/TB Core Group Meeting Addis Ababa, Ethiopia, 11-12 November 2008 Towards Universal Treatment Access Gains in Access to Care
TB Update: March 2012
TB Update: March 2012 David Schlossberg, MD, FACP Medical Director, TB Control Program Philadelphia Department of Public Health 1 TB Update: March 2012 IGRAs vs TST LTBI A New Regimen NAATs What is Their
Treatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis
Weekly Moxifloxacin and Rifapentine Is More Active Than the Denver Regimen in Murine Tuberculosis Ian M. Rosenthal, Kathy Williams, Sandeep Tyagi, Andrew A. Vernon, Charles A. Peloquin, William R. Bishai,
New TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009
TB in the Correctional Setting Collinsville, Illinois April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD, MPH April 22, 2009 Tuberculosis, HIV, and Corrections James B. McAuley, MD
TB/HIV management survey
TB/HIV management survey! Baseline audit in parallel with guidelines development process! Survey of clinician opinion and practice! Data collection from October 2004 to January 2005! Data was received
What are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
Pharmacology Update Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005
Pharmacology Update 2005 Alice Tseng, Pharm.D., FCSHP Vancouver May 11, 2005 I m having a Maalox moment!!! Gastric Hypoacidity in HIV 20% incidence in HIV (unrelated to CD 4 ) Antacids, ddi tablets, H2-blockers
Treatment of Latent TB Infection (LTBI)
Treatment of Latent TB Infection (LTBI) Mahesh C. Patel, MD June 14, 2017 2014 MFMER slide-1 Mahesh C. Patel, MD Associate Professor Treatment of LTBI Department of Internal Medicine, Division of Infectious
Integrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
Nurse Case Management Phoenix, Arizona February 20-22, 2008
Nurse Case Management Phoenix, Arizona February 20-22, 2008 TB/HIV: Managing the Co-Infected Patient Adriana Vasquez, MD February 21, 2008 HIV Treatment Guidelines DHHS December 1,2007 TB/HIV Managing
What is drug resistance? Musings of a clinician
What is drug resistance? Musings of a clinician William Burman MD Denver Public Health Tuberculosis Trials Consortium Financial disclosures Tibotec (developer of TMC207 and several antiretroviral drugs)
Development of New Regimens for Tuberculosis Zhenkun Ma, Ph.D.
Development of New Regimens for Tuberculosis Chief Scientific Officer Global Alliance for TB Drug Development 40 Wall Street, 24th Floor New York, NY 10005 USA 1 Outline What are the unmet needs in TB
TB Expert Network Conference 9/26/2008
TB Expert Network Conference 9/26/2008 Case 1-KT1 35 y/o AA male with a history of HIV since 2002. Presented in July 2007 to a hospital in Orlando, FL with 1 month history of productive cough, fevers and
The next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
Pre-Treatment Evaluation. Treatment of Latent TB Infection (LTBI) Initiating Treatment: Patient Education. Before initiating treatment for LTBI:
Pre-Treatment Evaluation Before initiating treatment for LTBI: Treatment of Latent TB Infection (LTBI) Amee Patrawalla, MD Associate Professor, New Jersey Medical School Attending Physician, NJMS Global
TB and Comorbidities Adriana Vasquez, MD April 12, 2018
TB and Comorbidities Adriana Vasquez, MD April 12, 2018 TB Nurse Case Management April 10 12, 2018 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Adriana Vasquez, MD has the following disclosures to make:
Treatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe
HIV Drug Resistance among Adolescents and Young Adults Failing HIV Therapy in Zimbabwe V Kouamou 1, J Manasa 1, D Katzenstein 1, A McGregor 1, CE Ndhlovu 1 & AT Makadzange 1. 1 University of Zimbabwe Introduction
Treatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose
Disclosures Updates in Tuberculosis I have nothing to disclose Chris Keh, MD Assistant Clinical Professor, Division of Infectious Diseases, UCSF TB Controller, TB Prevention and Control Program, Population
Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation
Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and
Overview Treatment of latent TB infection Meta-analysis 36 months of IPT Screening for TB Adverse events INH Resistance IPT & ART TST Conclusions
202/03/28 Isoniazid preventive therapy: evidence for safety and efficacy Clinician s course Gavin Churchyard/ Liesl Page-Shipp 6 March 202 Overview Treatment of latent TB infection Meta-analysis 36 months
Tuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
Second and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
PAEDIATRIC TB TRIAL UPDATE
PAEDIATRIC TB TRIAL UPDATE ANNEKE C. HESSELING PROFESSOR IN PAEDIATRICS AND CHILD HEALTH DIRECTOR: DESMOND TUTU TB CENTRE DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH STELLENBOSCH UNIVERSITY, SOUTH AFRICA
TB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis
Pharmacokinetics (PK) and Pharmacodynamics (PD) in the Treatment of Tuberculosis Shaun E. Gleason, PharmD, MGS Associate Professor, Department of Clinical Pharmacy Director, Distance Degrees and Programs
Clinical Trials Lecture 4: Data analysis
Clinical Trials Lecture 4: Data analysis Dick Menzies, MD Respiratory Epidemiology and Clinical Research Unit Montreal Chest Institute TB Research methods course July 17, 2014 Lecture 4: Data analysis
Drug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
Ongoing research on LTBI treatment and IMPAACT4TB
Ongoing research on LTBI treatment and IMPAACT4TB GJ Churchyard MBBCh (WITS), FCP (SA), FRCP (Edin), MMED (Int Med), PhD (WITS) 1 st September 2017 Who and when? PLHIV Household contacts High risk communities
Tuberculosis: Where Are We Now?
Tuberculosis: Where Are We Now? Amee Patrawalla MD MPH Rutgers - NJ Medical School Global TB Institute Rutgers, The State University of New Jersey Learning Objectives Understand the current epidemiologic
Co-morbidities that Impact Managing TB Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Co-morbidities that Impact Managing TB Lisa Armitige, MD, PhD November 17, 2010 Co-morbidities in Substance Abuse that Impact
A BS TR AC T. n engl j med 365;1 nejm.org july 7,
The new england journal of medicine established in 1812 july 7, 2011 vol. 365 no. 1 New Regimens to Prevent Tuberculosis in Adults with HIV Infection Neil A. Martinson, M.B., B.Ch., M.P.H., Grace L. Barnes,
Treatment of Tuberculosis
Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis
Kimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
Drug Interactions in TB / HIV Co-infected Patients
Drug Interactions in TB / HIV Co-infected Patients Saye Khoo HIV Pharmacology Group University of Liverpool / Biomedical Research Centre in Microbial Diseases HIV and TB prevalence Menu HIV TB drug interactions
Marcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
A review of rifapentine for treating active and latent tuberculosis
tive & omes A review of rifapentine for treating active and latent tuberculosis Background: Nearly 1/3 of the world s population is infected with Mycobacterium tuberculosis (Mtb). Simple, effective treatment
Ruth Moro M.D., M.P.H. Medical Epidemiologist. CDC, Division of Tuberculosis Elimination Clinical Research Branch Tuberculosis Trials Consortium
Factors Associated with Non-completion of Latent Tuberculosis Infection (LTBI) Treatment: Reasons other than Adverse Events (AE) The TB Trials Consortium PREVENT TB Study 26 Ruth Moro M.D., M.P.H. Medical
Chapter 5 Treatment for Latent Tuberculosis Infection
Chapter 5 Treatment for Latent Tuberculosis Infection Table of Contents Chapter Objectives.... 109 Introduction.... 111 Candidates for the Treatment of LTBI... 112 LTBI Treatment Regimens.... 118 LTBI
What more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings?
What more is required to use rifamycin regimens to prevent TB in people living with HIV in resource constrained settings? Gary Maartens Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI
TB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS
TB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS ANNEKE C. HESSELING RESIST TB WEBINAR 20 APRIL 2017 DESMOND TUTU TB CENTRE PROFESSOR IN PAEDIATRICS AND CHILD
SA TB Guidelines The interface with Advanced Clinical Care
SA TB Guidelines The interface with Advanced Clinical Care Dr Kogie Naidoo (MBCHB, PHD) Head: CAPRISA Treatment Research Programme Honorary Lecturer - UKZN Department of Public Heath Medicine Annual Workshop
1/18/2011. Handling TB and HIV. Fargo, North Dakota September 15-16, Treatment of TB in the HIV Co-Infected Patient
1/18/2011 Handling TB and HIV Co-Infection Fargo, North Dakota September 15-16, 2010 Treatment of TB in the HIV Co-Infected Patient Dean Tsukayama, MD September 15, 2010 1 Co-infection with TB and HIV
A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality
A Randomized Clinical Trial Comparing 6 EH vs 36H for TB Prevention in HIV-infected Adults in south India: Impact on Mortality Soumya Swaminathan,, PA Menon,, P Venkatesan et al Indian Council of Medical
The Elimination of Tuberculosis. Richard E. Chaisson, MD. Center for TB Research Center for AIDS Research Johns Hopkins University
The Elimination of Tuberculosis Richard E. Chaisson, MD Center for TB Research Center for AIDS Research Johns Hopkins University Disclosures Spouse owns Merck stock Consultant: Merck Research funding:
INH Preventive Therapy in. Mark F Cotton KID-CRU & Division of Pediatric Infectious Diseases, TygerbergChildren s Hospital & Stellenbosch University
INH Preventive Therapy in Children Mark F Cotton KID-CRU & Division of Pediatric Infectious Diseases, TygerbergChildren s Hospital & Stellenbosch University Prophylactic effect of INH on primary TB in
Overcoming the Challenges in Access to TB Drugs for Children
Overcoming the Challenges in Access to TB Drugs for Children Gregory L. Kearns, PharmD, PhD Professor of Pediatrics and Pharmacology, University of Missouri Marion Merrell Dow / Missouri Chair in Pediatric
Newer anti-tb drugs and regimens. DM Seminar
Newer anti-tb drugs and regimens DM Seminar 31-10-14 Why are newer drugs/regimens needed? Problems with current drugs/regimens Drug resistance Drug interaction of anti-tubercular drugs with ART Long duration
Issues in TB Drug Development: TB/HIV
Issues in TB Drug Development: TB/HIV Open Forum Gavin Churchyard 18 th August 2010 Presentation outline TB/HIV Epidemiology clinical aspects HIV associated TB Drug-Drug interactions Immunotherapy Latent
WESTERN CAPE ART GUIDELINES PRESENTATION 2013
WESTERN CAPE ART GUIDELINES PRESENTATION 2013 The WC guidelines are based on SA National ART guidelines dated 24th March 2013 Acknowledgement goes to members of the Adult and Paediatric HAST policy advisory
Historic Perspective on HIV and TB Research in Pregnant Women
Historic Perspective on HIV and TB Research in Pregnant Women Lynne M. Mofenson, M.D. Senior HIV Technical Advisor Elizabeth Glaser Pediatric AIDS Foundation High Burden of TB/HIV in Women - 2016 TB HIV
Continuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
Treatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features